KZA (ASX) KZA Media Thread

And the way I describe it is that

Kazia is powering on with minimal capital raising from inflection point to point, further proving the compounds and getting results better than the standard of care, attracting world class collaborations where the research party is pouring in their hard won resources and each time we see the conditions ahead we reassess and recalibrate to market conditions and prudently adjust as required to make sure the company is sound and the trials have the resources they need to continue their good works for both the patients and the investor.

in the last couple of years we have had multiple trials open up with multiple independent partners and we are entering a pivotal study with GBM Agile this year - we have reported multiple good results from 3 data readouts in the last 6 months which have propelled us into GBM Agile and shown excellent progress with Cantrixil.

But do your own research on this companies' finances and its capital raising history it’s recent remarkable good results as well as its multiple collaborations and particularly research these partner collaborators... there is none better worldwide in oncology.

We know what we are building here is an incredible foundation and a process which will allow us to expand our stable of compounds partnerships and benefits to patients and investors.

its great to see - for those of us invested - that the company has secured funding to continue its good work through this period of turmoil on world markets...

as some rightly point out even large banks are struggling - yet quickly and nimbly and astutely we have launched and closed on sophisticated investors for 7.2 mill having already 6 mill in the bank at the start of the year and are allowing retail to be involved in a raise for probably 1-3 million more and we did not currently need this - but which is clearly very prudent given macro conditions.

we were one of the first to secure funds - this says all it needs to about how our management team is building and protecting our core assets for us and has a plan way beyond this period not only for our fiat two compounds but for the over arching strategy of the company and its plan to continue this process across other candidates.

yet again we lead in this sector as a new breed of biotech.